Clinical Trials Logo
  1. Home
  2. Chikungunya
  3. NCT03992872

Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) — WRAIR  

Chikungunya Clinical Trial

Official title:
A Phase 2 Open-label Study to Assess the Safety and Immunogenicity of an Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) in Prior Recipients of Other Alphavirus Vaccines Versus Alphavirus Naïve Controls.

Clinical Trial Summary

This is a Phase 2 parallel-group age- and gender-matched open label study in healthy adults 18-65 years of age to assess the safety and immunogenicity of an alum-adjuvanted chikungunya virus-like particle vaccine (PXVX0317) in prior recipients of other alphavirus vaccines versus alphavirus naïve controls.

Clinical Trial Description

It is currently unknown whether prior exposure to heterologous alphaviruses will enhance or interfere with immune responses to chikungunya virus (CHIKV) exposure or vaccination. The objective of this study is to evaluate the safety and immunogenicity of the chikungunya vaccine candidate PXVX0317 when administered to prior recipients of experimental alphavirus vaccines versus alphavirus naïve gender- and age-matched controls. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03992872
Study type Interventional
Source Bavarian Nordic
Contact
Status Completed
Phase Phase 2
Start date November 20, 2019
Completion date January 19, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT04440774 - Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico. Phase 1
Recruiting NCT05153018 - Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu N/A
Active, not recruiting NCT04343521 - Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases Phase 3
Completed NCT03382964 - Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Phase 1
Completed NCT02831699 - The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
Recruiting NCT01099852 - Cohort of Patients Infected by an Arbovirus
Completed NCT06257810 - Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa Phase 4
Suspended NCT05218304 - Baromètre Santé Adulte 2021-2022 N/A
Recruiting NCT04615364 - Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
Active, not recruiting NCT04650399 - A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents Phase 3
Not yet recruiting NCT04672577 - Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria
Completed NCT04434846 - Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
Recruiting NCT04838574 - Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Recruiting NCT04619823 - Virological and Immunological Determinants of Arbovirus Infection in New Caledonia N/A
Completed NCT03101111 - Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area Phase 2
Completed NCT02463968 - Chikungunya Arthritis in the Americas N/A
Active, not recruiting NCT04566484 - Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia Phase 2/Phase 3
Completed NCT04603131 - Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine Phase 1